Biotech Showcase 2016

Oculis will attend be attending the 8th Annual Conference Biotech Showcase 2016 in San Francisco, CA. The conference takes place on January 11-13, 2016.

Appointment of Scientific and Medical Advisory Board

Oculis today completed the formation of a new Scientific and Medical Advisory Board. The Advisory Board consists of five members with vast experience from ophthalmology and the pharmaceutical industry.

Favorable results of DexNP eye drops for DME in a phase II trial

A new article has recently been published on the efficacy and safety of DexNP eye drops in DME patients, demonstrating that use of DexNP significantly improves visual acuity and decreases macular thickness in patients with DME.

Presentation at ISOPT Clinical

Dr. Einar Stefansson, Oculis’ Chairman and Dr. Akihiro Ohira, member of Oculis’ Scientific and Medical Advisory Board, will both present at ISOPT Clinical meeting in Berlin results of pre-clinical studies involving the Oculis platform.

Three new Board Members

At Oculis’s AGM today, Dr. Joseph Markoff, Dr. James D. Pipkin and Dr. George Mooney were elected to Oculis’ Board of Directors.

New Organizational Chart

Today, Oculis’ Board of Directors approved a new Organizational Chart for the Company reflecting the recent additions to the company’s management.

Poster Presentation at ARVO

The results of a phase II studies in DME of Oculis’ most advanced drug candidate, DexNP will be presented at the 2015 ARVO meeting in Denver.

Poster Presentation at AAO Annual Meeting

Results from a pilot study on DexNP, Oculis’ most advanced drug candidate, in uveitis, will be presented at the 2014 Annual Meeting of the American Academy of Ophthalmology held in Chicago, IL, 18-21 October 2014.